Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Allergen immunotherapy (14)
  • Allergy asthma and a sport (1)
  • Allied health and primary care (8)
  • Anaphylaxis (2)
  • Artificial Intelligence (1)
  • Asthma (1)
  • Biologicals (11)
  • Drug allergy (1)
  • Food allergy (9)
  • Immune deficiencies and autoimmunity (1)
  • Insect venom hypersensitivities (2)
  • Pediatrics (11)
  • Prevention (2)
Poster available until
Poster categories
  • Thematic Poster Session (34)
keywords
Session Reference
  • L-TPS01 (11)
  • L-TPS02 (15)
  • L-TPS03 (14)
  • L-TPS04 (12)
  • L-TPS05 (13)
  • L-TPS06 (8)
  • L-TPS07 (11)
  • L-TPS08 (7)
  • L-TPS09 (13)
  • L-TPS10 (13)
  • L-TPS11 (12)
  • L-TPS12 (14)
  • L-TPS13 (13)
  • L-TPS14 (11)
  • L-TPS15 (7)
  • L-TPS16 (14)
  • L-TPS17 (13)
  • L-TPS18 (10)
  • L-TPS19 (10)
  • L-TPS20 (12)
  • L-TPS21 (12)
  • TPS01 (12)
  • TPS02 (8)
  • TPS03 (14)
  • TPS04 (9)
  • TPS05 (15)
  • TPS06 (11)
  • TPS07 (13)
  • TPS08 (9)
  • TPS09 (9)
  • TPS10 (16)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (15)
  • TPS16 (15)
  • TPS17 (12)
  • x TPS18 (10)
  • TPS19 (7)
  • TPS20 (11)
  • TPS21 (5)
  • TPS22 (3)
  • TPS23 (4)
  • TPS25 (12)
  • TPS26 (14)
  • TPS27 (12)
  • TPS28 (16)
  • TPS29 (16)
  • TPS30 (14)
  • TPS31 (15)
  • x TPS32 (16)
  • TPS33 (14)
  • TPS34 (17)
  • TPS35 (15)
  • TPS36 (12)
  • TPS37 (15)
  • TPS38 (13)
  • TPS39 (14)
  • TPS40 (13)
  • TPS41 (9)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (8)
  • TPS47 (7)
  • TPS48 (5)
  • TPS49 (5)
  • TPS51 (12)
  • TPS52 (14)
  • TPS53 (8)
  • TPS54 (15)
  • TPS55 (13)
  • TPS56 (16)
  • TPS57 (12)
  • TPS58 (12)
  • TPS59 (13)
  • TPS60 (14)
  • TPS61 (11)
  • TPS62 (9)
  • TPS63 (10)
  • TPS64 (11)
  • TPS65 (8)
  • TPS66 (9)
  • TPS67 (9)
  • TPS68 (19)
  • x TPS69 (8)
  • TPS70 (9)
  • TPS71 (11)
  • TPS72 (6)
  • TPS73 (5)
  • TPS75 (4)
34 results
Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Thumbnail

D2.150 - Safety and efficacy of a 7-week immunotherapy protocol with aluminum hydroxide adsorbed bee venom

Thumbnail

D2.159 - Real-World Protective Effects of Epicutaneous Immunotherapy in Peanut-allergic Toddlers

Thumbnail

D2.149 - EFFECTIVENESS AND SAFETY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY WITH Pru p3 EXTRACT IN PATIENTS WITH LTP ALLERGY

Thumbnail

D2.151 - Study design for A multicenter, open label, randomized Study to inveStigate the effIcacy of Subcutaneous immunoTherapy combined with vitamin D3 in children and adolescent patients with allergic rhinitis (ASSIST study)

Thumbnail

D2.152 - Study design for the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders: a multicenter prospective observational study (CALM study)

Thumbnail

D2.153 - Allergenicity and Immunogenicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus‐Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy

Thumbnail

D2.154 - Real-life observational study on the effectiveness of a broad-spectrum allergen product in unresponsive pediatric patients

Thumbnail

D2.155 - Factors associated with higher serum IgG4 response in children treated with allergen immunotherapy

Thumbnail

D2.156 - Study on the Effect of the Mucosal Vaccine MV130 on Innate Immunity Factors in School-Age Children

Thumbnail

D2.157 - Peanut allergen-loaded microneedle array patch modulates the immune response to peanut allergy in Balb/c and C3H/HeJ mouse model

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM